Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid

In Vivo

Volumn 18, Issue 2, 2004, Pages 189-196

  Nasir, Aejaz ^a   Catalano, Edison ^b   Calafati, Stephanie ^b   Cantor, Alan ^a   Kaiser, Hans E ^c   Coppola, Domenico ^d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Department of Anesthesiology   (United States)

^c Intl Soc Stud Compar Oncol   (United States)

^d CytoCor   (United States)

Author keywords

Bcl 2; CD44V6; CD57; Diffential diagnosis; Follicular lesions; p53; Thyroid

Indexed keywords

BIOLOGICAL MARKER; CD44V6 ANTIGEN; CD57 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MALIGNANT NEOPLASTIC DISEASE; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID CANCER; THYROID FOLLICLE; THYROID SURGERY; TUMOR VOLUME;

EID: 1842863616     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Oertel J and LiVolsi VA: Pathology of the thyroid. In: Ingbar SH, Braverman LE, eds. Werner's The thyroid. 6th ed. Philadelphia: JB Lippincott, 1991. p.603-642.
2. Evans HL: Follicular neoplasms of the thyroid. Cancer 54: 535-40, 1984.
3. Franssila KO, Ackerman LV, Brown CL and Hedinger CE: Follicular carcinoma. Semin Diagn Pathol 2: 101-122, 1985.
4. Kahn N and Perzin KH. Follicular carcinoma of the thyroid: an evaluation of the histologic criteria used for diagnosis. Pathol Annu 18 (part 1): 221-253, 1983.
5. Burgart, L, Reid R, Robinson R and Platz C: Follicular neoplasms of the thyroid: a clinicopathologic comparison of neoplasms diagnosed as follicular carcinoma and follicular adenoma with 10 year minimum follow-up. Mod Pathol 4: 32A, 1991.
6. Lang W, Georgii A, Stauch G and Kienzle E: The differentiation of atypical adenoma and encapsulated follicular carcinomas in the thyroid gland. Virchows Arch 385(A): 125-141, 1980.
7. Santoro M, Grieco M, Melillo RM, Fusco A and Vecchio G: Molecular defects in thyroid carcinomas: Role of the RET oncogene in thyroid neoplastic transformation. Eur J Endocrin 133: 513-522, 1995.
8. Wyllie FS, Haughton MF, Blaydes JP, Schlumberger M and Wynford-Thomas D: Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells. Oncogene 10: 49-59, 1995.
9. Harvey M, Vogel H, Lee EY-HP, Bradley A and Donehower LA: Mice deficient in both p53 and Rb development tumors primarily of endocrine origin. Cancer Res 55: 1146-1151, 1995.
10. Holm R and Nesland JM: Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 172: 267-272, 1994.
11. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi Y, Kohi K, Nakamura N and Akiyama M: Genetic alterations in thyroid tumor progression: Association with p53 gene mutations. Jpn J Cancer Res 84: 526-531, 1993.
12. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspendblad U, Hoog A, Borresen AL and Auer G: Alterations of p53 and expression of WAF1/p2 in human thyroid tumors. Thyroid 6: 1-9, 1996.
13. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G and Pierotti M: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91: 1753-1760, 1993.
14. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T and Machinami R: Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg pathol 17: 375-381, 1993.
15. Fagin JA, Matsuo K, Karmaker A, Chen DL, Tang S-H and Koeffler HP: High prevalence of mutations of the P53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184, 1993.
16. Dobashi Y, Sugimura H, Sakamoto A, Mernyei M, Mori M, Oyama T and Machinami R: Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Molec Pathol 3: 9-14, 1994.
17. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A and Pontecorvi A: P53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 14: 729-740, 1997.
18. Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B: CD44 is the principle cell surface receptor for hyaluronate. Cell 1: 1303-13, 1990.
19. Jalkanen S, Bargatze RF, Herron LR and Butcher EC: A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol 16: 1195-1202, 1986.
20. Cooper DL, Dougherty G, Harn HJ, Jackson S, Baptist EW, Byers J et al: The complex CD44 transcriptional unit: alternative splicing of three internal exons generates the epithelial form of CD44. Biochem Biophys Res Commun 182: 569-78, 1992.
21. Screaton GR, Bell MV, Jackson DG, Coenelis FB, Gerth U and Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 112 alternative spliced exons. Proc Natl Acad 89: 12160-64, 1992.
22. Guriec N, Marcellin L, Garirard B, Calderoli H, Wilk A, Renaud R et al: CD44 exon expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin Exp Met 14: 434-39, 1996.
23. Harn HL, Ho LL Chang JY, Wu CW, Jiang SY, Lee HS et al: Differential expression of the human metastasis adhesion molecule CD44V in normal and carcinomatous stomach mucosa of chinese subjects. Cancer 75: 1065-71, 1995.
24. Roye GD, Myers RB, Brown D, Poczatek R, Beenken SW and Grizzle WE: CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus. Int J Cancer 69: 254-58, 1996.
25. Ermak G, Gerasimov G, Troshina K, Jennings T, Robinson L, Ross JS and Figge J: Deregulated alternative splicing of CD44 messenger RNA transcripts in neoplastic and nonneoplastic lesions of the human thyroid. Cancer Res 55: 4594-4598, 1995.
26. Ermak G, Jennings T, Robinson L, Ross JS and Figge J: Restricted patterns of CD44 variant exon expression in human papillary thyroid carcinoma. Cancer Res 56: 1037-1042, 1996.
27. Figge J, Del Rosario, AD, Gerasimov G, Dedov I, Bronstein M, Troshina K, Alexandrova G, Kallakury BVS, Bui HX, Bratslavsky G and Ross JS: Preferential expression of the cell adhesion molecule CD44 in papillary thyroid carcinoma. Exp Molec Pathol 61: 203-211, 1994.
28. Sy MS, Guo YJ and Stamenkovic I: Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 174: 859-66, 1991.
29. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haubmann I et al: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991.
30. Hofmann M, Rudy W, Zoller M, Tolg C, Ponta H, Herrlich P and Gunthert U: CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 51: 5292-97, 1991.
31. Branet F, Caron P, Camallieres M, Selves J and Brousset P: Bcl-2 proto-oncogene expression in neoplastic and non neoplastic thyroid tissue. Bull du Cancer 56: 213-217, 1996.
32. Branet F, Brousset P, Krajewski S, Schlaifer D, Selves J, Reed JC and Caron P: Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. J Clin Endocrin Metab 81: 2726-2730, 1996.
33. Abo T and Balch CMA: A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol 127: 1024-1029, 1981.
34. Lanier LL, Le AM, Phillips JH, Warner NL and Babcock GF: Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 131: 1789-1795, 1983.
35. Kruse J, Mailhammer R, Wernecke H, Faissner A, Sommer I, Goridis C and Schachner M: Neural cell adhesion molecules and myelin-associated glycoprotein share a common carbohydrate moiety recognized by monoclonal antibodies L2 and HNK-1. Nature 311: 153-155, 1984.
36. Ghali VS, Jimenez JS and Garcia RL: Distribution of Leu-7 antigen (HNK-1) in thyroid tumors: its usefulness as a diagnostic marker for follicular and papillary carcinomas. Hum Pathol 23: 21-25, 1992.
37. Fucich LF, Freeman SM and Marrogi AJ: An immunohistochemical study of leu-7 and PCNA expression in thyroid neoplasms. Biotech Histochem 71: 298-303, 1996.
38. Ostrowski ML, Brown RW, Wheeler TM, Green LK and Schaffner DL: Leu-7 immunoreactivity in cytologic specimens of thyroid lesions, with emphasis on follicular neoplasms. Diagn Cytopathol 12: 297-302, 1995.
39. Loy TS, Darkow GV, Spollen LE and Diaz-Arias AA: Immunostaining for Leu-7 in the diagnosis of thyroid carcinoma. Arch Pathol Lab Med 118: 172-174, 1994.
40. Shi SR, Key ME and Kalza KL: Antigen retrieval in formalin-fixed paraffin-embedded tissues. An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-48, 1991.
41. Czyz W, Joensuu H, Pylkkanen L and Klemi PJ: P53 protein, PCNA staining, and DNA content in follicular neoplasms of the thyroid gland. J Pathol 174: 267-274, 1994.
42. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang S-H and Koeffler HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179-184, 1993.
43. Nishida T, Nakao K, Hamaji M, Nakahara MA and Tsujimoto M: Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Surgery 119: 568-575, 1996.
44. Zou M, Shi Y, al-Sedairy S, Hussain SS and Farid NR: The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis. Cancer 76: 314-318, 1995.
45. Gerasimov G, Bronstein M, Troshina K, Alexandrova G, Dedov I, Jennings T, Kallakury BV, Izquierdo R, Boguniewicz A, Figge H et al: Nuclear p53 immunoreactivity in papillary thyroid cancers is associated with two established indicators of poor prognosis. Exp Mol Pathol 62: 52-62, 1995.
46. Dougherty GJ, Lansdorp PM, Cooper DL and Humphries RK: Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte "homing" receptor expressed by hematopoietic. J Exp Med 174: 1-5, 1991.
47. Sleeman J, Moll J, Sherman L, Dall P, Pals ST, Ponta H and Herrlich P: The role of CD44 splice variants in human metastatic cancer. Cell Adhesion and Human Disease. Wiley, Chichester (Ciba Foundation Symposium 189) pp 142-156, 1995.
48. Gunthert AR, Strater J, von ReyherU, Henne C, Joos S, Kortez K, Moldenhauer G, Krammer PH and Moller P: Early detachment of colon carcinoma cells during CD95 (APO-1/Fas)-mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44. J Cell Biol 134(4): 1089-1096, 1996.
49. Smolle J, Walter GF and Kerl H: Myelin-associated glycoprotein in neurogenic tumours of the skin: an immunohistological study using Leu-7 monoclonal antibody. Arch Dermatol Res 277: 141-142, 1995.
50. Swanson PE, Manivel JC and Wick MR: Immunoreactivity for Leu-7 in neurofibrosarcoma and other spindle cell sarcomas of soft tissue. Am J Pathol 126: 546-560, 1987.
51. Lipinski M, Braham K, Calillaud J-M, Carlu C and Tursz T: HNK-1 antibody detects an antigen expressed on neuroectodermal cells. J Exp Med 158: 1775-1780, 1983.
52. Caillaud J-M, Benjelloun S, Bosq J, Braham K and Lipinski M: HNK-1-defined antigen detected in paraffin-embedded neuroectoderm tumors and those derived from cells of the amine precursor uptake and decarboxylation system. Cancer Res 44: 4432-4439, 1984.
53. Llombart-Bosch A, Lacombe MJ, Peydro-Olaya A, Perez-Bacete M and Contesso G: Malignant peripheral neuroectodermal tumours of bone other than Askin's neoplasm: characterization of 14 new cases with immunohistochemistry and electron microscopy. Virchows Arch A Pathol Anat Histopathol 412: 421-430, 1988.
54. Bunn PA Jr, Linnoila I, Minna JD, Carney D and Gazdar AF: Small cell lung cancer, endocrine cells of the fetal bronchus, and other neuroendocrine cells express the Leu-7 antigenic determinant present on natural killer cells. Blood 65: 764-768, 1985.
55. Ostrowski ML, Brown RW, Wheeler TM, Green LK and Schaffner DL: Leu-7 immunoreactivity in cytologic specimens of thyroid lesions, with emphasis on follicular neoplasms. Diagn Cytopathol 12: 297-302, 1995.
56. Loy TS, Darkow GV, Spollen LE and Diaz-Arias AA: Immunostaining for Leu-7 in the diagnosis of thyroid carcinoma. Arch Pathol Lab Med 118: 172-174, 1994.
57. Fuchich LF, Freeman SM and Marrogi AJ: An immunohistochemical study of Leu-7 and PCNA expression in thyroid neoplasms. Biotech Histochem 71: 298-303, 1996.
58. Monaghan P, Robertson D, Amos TAS, Dyer MJS, Mason DY and Greaves MF: Ultrastructural localization of Bcl protein. J Histochem Cytochem 40: 1819-1825, 1992.
59. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, LandH, Brooks M, Waters CM, Penn LZ and Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128, 1992.
60. Okayasu I, Saegusa M, Fujiwara M, Hara Y and Rose NR: Enhanced cellular proliferative activity and cell death in chronic thyroiditis and thyroid papillary carcinoma. J Cancer Res Clin Oncol 121:746-752, 1995.
61. Pollina L, Pacini F, Gontanini G, Vignati S, Bevilacqua G and Basolo F: Bcl-2 p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer 73: 139-143, 1996.
62. Basolo F, Pollina L, Fontanini G, Fiore L, Pacini F and Baldanzi A: Apoptosis and proliferation in thyroid carcinoma: Correlation with bcl-2 and p53 protein expression. Br J Cancer 75: 537-541, 1997.